vs

Side-by-side financial comparison of GREENPOWER MOTOR Co INC. (GP) and Verrica Pharmaceuticals Inc. (VRCA). Click either name above to swap in a different company.

Verrica Pharmaceuticals Inc. is the larger business by last-quarter revenue ($14.3M vs $7.2M, roughly 2.0× GREENPOWER MOTOR Co INC.). Verrica Pharmaceuticals Inc. runs the higher net margin — -1.9% vs -65.6%, a 63.7% gap on every dollar of revenue. On growth, Verrica Pharmaceuticals Inc. posted the faster year-over-year revenue change (905.4% vs -11.5%).

GreenPower Motor Company Inc. is a Canadian electric bus manufacturer and distributor in North America. The company fabricates multiple zero-emission models, including transit buses, school buses, and double decker buses. GreenPower headquarters are in Vancouver, British Columbia, with a sales office in Rancho Cucamonga, California; an assembly facility in Porterville, California; and a production facility in South Charleston, West Virginia. Its stock is traded on Nasdaq the United States.

Verrica Pharmaceuticals Inc. is a clinical-stage biopharmaceutical firm focused on developing and commercializing innovative prescription treatments for common and rare dermatological conditions. It primarily serves North American patients and healthcare providers, delivering solutions for unmet needs in dermatology care.

GP vs VRCA — Head-to-Head

Bigger by revenue
VRCA
VRCA
2.0× larger
VRCA
$14.3M
$7.2M
GP
Growing faster (revenue YoY)
VRCA
VRCA
+916.9% gap
VRCA
905.4%
-11.5%
GP
Higher net margin
VRCA
VRCA
63.7% more per $
VRCA
-1.9%
-65.6%
GP

Income Statement — Q3 FY2025 vs Q3 FY2025

Metric
GP
GP
VRCA
VRCA
Revenue
$7.2M
$14.3M
Net Profit
$-4.7M
$-274.0K
Gross Margin
14.6%
Operating Margin
11.3%
Net Margin
-65.6%
-1.9%
Revenue YoY
-11.5%
905.4%
Net Profit YoY
-2.1%
98.8%
EPS (diluted)
$-0.17
$-0.03

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
GP
GP
VRCA
VRCA
Q3 25
$14.3M
Q2 25
$12.7M
Q1 25
$3.4M
Q4 24
$7.2M
$344.0K
Q3 24
$5.3M
$-1.8M
Q2 24
$3.0M
$5.2M
Q1 24
$3.8M
Q4 23
$8.2M
$2.0M
Net Profit
GP
GP
VRCA
VRCA
Q3 25
$-274.0K
Q2 25
$204.0K
Q1 25
$-9.7M
Q4 24
$-4.7M
Q3 24
$-4.7M
$-22.9M
Q2 24
$-5.4M
$-17.2M
Q1 24
$-20.3M
Q4 23
$-4.6M
$-24.6M
Gross Margin
GP
GP
VRCA
VRCA
Q3 25
Q2 25
Q1 25
79.6%
Q4 24
14.6%
Q3 24
8.6%
122.5%
Q2 24
7.4%
86.5%
Q1 24
81.7%
Q4 23
16.6%
Operating Margin
GP
GP
VRCA
VRCA
Q3 25
11.3%
Q2 25
11.9%
Q1 25
-236.4%
Q4 24
Q3 24
1162.5%
Q2 24
-293.7%
Q1 24
-486.1%
Q4 23
-1163.8%
Net Margin
GP
GP
VRCA
VRCA
Q3 25
-1.9%
Q2 25
1.6%
Q1 25
-283.3%
Q4 24
-65.6%
Q3 24
-87.9%
1283.5%
Q2 24
-179.8%
-332.0%
Q1 24
-531.4%
Q4 23
-56.9%
-1238.1%
EPS (diluted)
GP
GP
VRCA
VRCA
Q3 25
$-0.03
Q2 25
$0.02
Q1 25
$-0.10
Q4 24
$-0.17
Q3 24
$-0.18
$-4.88
Q2 24
$-0.21
$-3.70
Q1 24
$-0.44
Q4 23
$-0.19
$-0.55

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
GP
GP
VRCA
VRCA
Cash + ST InvestmentsLiquidity on hand
$621.1K
$21.1M
Total DebtLower is stronger
$21.6M
Stockholders' EquityBook value
$2.1M
$-17.0M
Total Assets
$37.4M
$40.9M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
GP
GP
VRCA
VRCA
Q3 25
$21.1M
Q2 25
$15.4M
Q1 25
$29.6M
Q4 24
$621.1K
$46.3M
Q3 24
$116.9K
$23.0M
Q2 24
$528.3K
$31.9M
Q1 24
$48.9M
Q4 23
$4.0M
$69.5M
Total Debt
GP
GP
VRCA
VRCA
Q3 25
$21.6M
Q2 25
$24.6M
Q1 25
$27.8M
Q4 24
$31.0M
Q3 24
$43.3M
Q2 24
$42.8M
Q1 24
$42.8M
Q4 23
$42.9M
Stockholders' Equity
GP
GP
VRCA
VRCA
Q3 25
$-17.0M
Q2 25
$-17.5M
Q1 25
$-18.6M
Q4 24
$2.1M
$-9.9M
Q3 24
$4.2M
$-34.1M
Q2 24
$8.6M
$-13.3M
Q1 24
$1.5M
Q4 23
$18.1M
$19.8M
Total Assets
GP
GP
VRCA
VRCA
Q3 25
$40.9M
Q2 25
$39.1M
Q1 25
$42.2M
Q4 24
$37.4M
$54.1M
Q3 24
$39.4M
$32.9M
Q2 24
$43.5M
$52.0M
Q1 24
$66.3M
Q4 23
$50.2M
$81.6M
Debt / Equity
GP
GP
VRCA
VRCA
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
28.41×
Q4 23
2.17×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
GP
GP
VRCA
VRCA
Operating Cash FlowLast quarter
$-1.1M
$9.7M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
0.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
GP
GP
VRCA
VRCA
Q3 25
$9.7M
Q2 25
$-10.0M
Q1 25
$-12.7M
Q4 24
$-1.1M
$-60.9M
Q3 24
$-1.3M
$-8.6M
Q2 24
$-3.2M
$-16.4M
Q1 24
$-19.9M
Q4 23
$1.4M
$-14.5M
Free Cash Flow
GP
GP
VRCA
VRCA
Q3 25
Q2 25
Q1 25
Q4 24
$-61.0M
Q3 24
$-8.6M
Q2 24
$-16.4M
Q1 24
Q4 23
$-14.7M
FCF Margin
GP
GP
VRCA
VRCA
Q3 25
Q2 25
Q1 25
Q4 24
-17719.2%
Q3 24
481.4%
Q2 24
-316.2%
Q1 24
Q4 23
-741.1%
Capex Intensity
GP
GP
VRCA
VRCA
Q3 25
0.0%
Q2 25
Q1 25
Q4 24
7.8%
Q3 24
-0.9%
Q2 24
0.2%
Q1 24
0.0%
Q4 23
11.4%
Cash Conversion
GP
GP
VRCA
VRCA
Q3 25
Q2 25
-49.24×
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
Q4 23

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

GP
GP

Segment breakdown not available.

VRCA
VRCA

License And Collaboration Revenue$10.7M75%
Products$3.6M25%

Related Comparisons